Level Four Advisory Services, LLC Aurinia Pharmaceuticals Inc. Transaction History

Level Four Advisory Services, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	SELL	$7.13 - $9.49 $109,089 - $145,197	-15,300 Reduced 6.07%	236,800 $2.13 Million
Q3 2023 Nov 13, 2023	BUY	$7.77 - $12.27 $20,979 - $33,129	2,700 Added 1.08%	252,100 $1.96 Million
Q2 2023 Jul 10, 2023	SELL	$8.96 - $11.69 $7,168 - $9,352	-800 Reduced 0.32%	249,400 $2.41 Million
Q1 2023 Jun 05, 2023	BUY	$5.94 - $11.27 $1.42 Million - $2.69 Million	239,000 Added 2133.93%	250,200 $2.74 Million
Q3 2022 Nov 07, 2022	BUY	$6.66 - $12.39 $6,660 - $12,390	1,000 Added 9.8%	11,200 $84,000
Q2 2022 Aug 08, 2022	BUY	$8.95 - $12.8 $91,290 - $130,560	10,200 New	10,200 $103,000
Q1 2022 May 10, 2022	SELL	$10.05 - $22.48 $107,032 - $239,412	-10,650 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$17.78 - $33.08 $189,357 - $352,302	10,650 New	10,650 $244,000

208

58.1M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.14B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Level Four Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Level Four Advisory Services, LLC with notifications on news.